A federal appeals court revived more than 500 lawsuits claiming that acetaminophen taken during pregnancy contributed to autism or ADHD, reversing the ruling that had shut the litigation down in 2023. If you took Tylenol while pregnant, here is the part the headlines mostly skipped: the decision did not find that acetaminophen causes anything, the defendants are asking the full court to reconsider it, and there is no settlement and nothing to claim.
Allegations Only · No Settlement Yet
This article describes pending product liability litigation. The claims described below are unproven allegations. No defendant has been found liable, no court has found that acetaminophen causes autism spectrum disorder or ADHD, there is no settlement fund, and there is nothing to claim at this time. This page is informational and is not legal or medical advice.
What Happened?
On July 13, 2026, the U.S. Court of Appeals for the Second Circuit reversed the dismissal of the federal acetaminophen autism and ADHD litigation and sent more than 500 cases back to the district court. The appeal is captioned Rutledge v. Walgreen Co., Nos. 24-916(L) and 24-2594, and the opinion was written by Judge Guido Calabresi.The cases had been dead since December 2023, when Judge Denise Cote of the Southern District of New York excluded the plaintiffs' general-causation experts and then entered judgment for the defendants across the multidistrict litigation. The Second Circuit held that the district court exceeded its discretion in excluding three of those experts, while upholding the exclusion of two others.
What the panel did not do matters as much as what it did. The court stated that it was not deciding whether acetaminophen causes autism or ADHD, and that it was not addressing what public health policy should be. This was a ruling about whether a jury may hear the plaintiffs' expert witnesses — not a scientific finding, and not a verdict.
Why the Ruling Is Not the End of It
The defendants are not accepting the panel's decision. According to Reuters, Kenvue and the pharmacy and retail chains asked the Second Circuit for an additional 45 days to prepare a petition for rehearing, telling the court that Kenvue's appellate counsel in the case had retired and that new lawyers needed time to come up to speed. A petition for rehearing asks the panel to reconsider, or the full court to take the case up again.Even if rehearing is denied, the fight over the experts is not finished. Kenvue has said publicly that it will challenge the reliability of the plaintiffs' expert evidence again once the cases are back before Judge Cote. Reinstating an expert on appeal returns the question to the trial court; it does not close it.
The district court docket shows the Second Circuit transmitting orders to Judge Cote on July 14 and July 20, 2026. As of August 3, 2026, no bellwether trial date, case management schedule or settlement discussion had been announced on the public record.
How the Litigation Got Here
The Judicial Panel on Multidistrict Litigation created MDL No. 3043 on October 5, 2022, consolidating what were then 18 actions plus 47 related cases before Judge Cote in the Southern District of New York. The plaintiffs alleged that they used over-the-counter generic acetaminophen while pregnant and that, as a result of prenatal exposure, their children developed autism spectrum disorder, ADHD, or both. The defendants opposed centralization and denied the allegations.The panel built the MDL as an industrywide proceeding rather than a company-by-company one, reasoning that general causation, the background science and the regulatory history would be substantially the same in every case regardless of which retailer sold the product. That is why the defendant list spans store brands from Walmart, CVS, Walgreens, Costco, Rite Aid, Safeway, Target and Family Dollar alongside claims involving branded Tylenol.
In December 2023 the district court found the plaintiffs' scientific evidence of general causation insufficient under the standard governing expert testimony, and the MDL was effectively over. Cases kept being filed anyway, and the court kept entering judgment against them — an April 1, 2026 order alone dismissed roughly 52 member cases with prejudice after their plaintiffs did not respond to an order to show cause. Those dismissals are part of what the July 2026 reversal now unsettles.
The Science Is Still Contested
This is the part that gets flattened in coverage. Research on prenatal acetaminophen exposure and neurodevelopmental outcomes has produced conflicting findings, and scientists disagree about what the association means. The Second Circuit's own framing was that the reinstated experts offered acceptable interpretations of scientific evidence in an area where scientists may, and do, disagree about the answer.Acetaminophen remains widely used and is not the subject of a recall. Decisions about pain relief or fever treatment during pregnancy belong with a physician, not with a litigation update. Nothing in the July 2026 ruling changes what any medical body recommends.
A Separate Dispute Over Confidential Documents
One other development on this docket is worth flagging because it involves one of the largest firms signing up Tylenol claimants, and because it has nothing to do with whether anyone's case is any good.In an opinion and order entered May 8, 2026, Judge Cote granted a sanctions motion brought by Johnson & Johnson Consumer Inc. and sanctioned plaintiffs' counsel Ashley Keller and Keller Postman LLC. Legal trade press reported that the sanction concerned the use of confidential documents produced in the MDL in related state court cases in Texas and Florida, in breach of the protective order governing that material. On June 3, 2026 the court ordered a $50,000 donation to March of Dimes in place of a fee award, to be made within 14 days of the May 8 order becoming final and non-appealable. Keller Postman has appealed.
To be clear about what this is and is not: it is a ruling about compliance with a discovery order, it is not a finding about the merits of any client's claim, and it is on appeal rather than final. It does not affect whether prenatal acetaminophen exposure caused anyone's injury.
What This Means If You Took Tylenol While Pregnant
Practically, nothing has become claimable. There is no settlement fund, no administrator, no claim form and no deadline attached to this litigation, and the revival did not award a dollar to anyone. Any site presenting a Tylenol autism "settlement payout" as something you can sign up to collect is describing something that does not exist.What did change is that the federal cases are alive again, which is the precondition for anything else ever happening. Individual claims of this kind are governed by state statutes of limitations that vary and can run out, so anyone weighing whether to pursue a claim should talk to a qualified attorney about their own facts and timing rather than waiting for a settlement announcement. Our standing Tylenol autism and ADHD investigation page tracks the case status as it develops, and the 2026 mass tort MDL tracker shows where MDL 3043 sits against the other active federal mass torts.
Sources
• U.S. Court of Appeals for the Second Circuit — opinion in Rutledge v. Walgreen Co. / Phippen v. Walgreen Co., Nos. 24-916(L), 24-2594 (July 13, 2026)• U.S. District Court, S.D.N.Y. — In re Acetaminophen ASD-ADHD Products Liability Litigation, MDL 3043
• Judicial Panel on Multidistrict Litigation — transfer order creating MDL No. 3043 (October 5, 2022)
• CourtListener — docket, In re Acetaminophen ASD-ADHD Products Liability Litigation, No. 1:22-md-03043 (S.D.N.Y.)
• Reuters via CNBC — U.S. appeals court revives private lawsuits linking Tylenol to autism (July 13, 2026)
• Kenvue — company statement on the Second Circuit ruling
• Opinion and Order entered May 8, 2026 and order entered June 3, 2026, In re Acetaminophen ASD-ADHD Products Liability Litigation, No. 1:22-md-03043 (S.D.N.Y.), as reported by legal trade press
Questions
Did the appeals court decide that Tylenol causes autism?
No. The Second Circuit said expressly that it was not deciding whether prenatal acetaminophen exposure causes autism spectrum disorder or ADHD, and that it was not addressing public health policy. The July 13, 2026 decision is about whether the plaintiffs' expert witnesses may testify under the standard governing expert evidence. The causation question remains contested and returns to the trial court.
Is there a Tylenol autism settlement or claim form?
No. There is no settlement fund, no claim form and no deadline to file a claim in this litigation. Reviving the cases means they may proceed in court; it does not award anyone money. Anyone who sees a website advertising a Tylenol autism settlement payout should treat it with caution.
Is the July 2026 ruling final?
Not yet. According to Reuters, Kenvue and the retailer defendants asked the Second Circuit for an additional 45 days to prepare a petition for rehearing, saying Kenvue's appellate counsel had retired and new lawyers needed time. If the full court agrees to reconsider, the panel decision could be revisited. Kenvue has also said it will challenge the reliability of the plaintiffs' experts again in the district court.
Which companies are defendants in this litigation?
The MDL was created as an industrywide proceeding covering store-brand acetaminophen sold by retailers including Walmart, CVS, Walgreens, Costco, Rite Aid, Safeway, Target and Family Dollar, alongside claims involving branded Tylenol, now sold by Kenvue. The defendants deny the allegations and no company has been found liable.
What were the reinstated experts allowed to say?
The panel held that the district court exceeded its discretion in excluding three of the plaintiffs' general-causation experts, describing them as qualified experts whose opinions comport with methodologies applied by other scientists in their fields. It held the district court acted within its discretion in excluding two others. Admissibility is not a finding that the opinions are correct — a jury would still have to weigh them against the defense evidence.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
